This study will evaluate the effects of anacetrapib (MK-0859) on low-density lipoprotein-cholesterol (LDL-C) when compared to placebo in Japanese participants with heterozygous familial hypercholesterolemia when added to an existing statin lipid-modifying therapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
68
Percent Change from Baseline in LDL-C (beta-quantification [BQ] method)
Time frame: Baseline and Week 12
Percentage of Participants who Experience at Least One Adverse Event (AE)
Time frame: 12 weeks
Percent Change from Baseline in High-density Lipoprotein-cholesterol (HDL-C)
Time frame: Baseline and Week 12
Percent Change from Baseline in Non-HDL-C
Time frame: Baseline and Week 12
Percent Change from Baseline in Apolipoprotein A-I (Apo-A-I)
Time frame: Baseline and Week 12
Percent Change from Baseline in Apolipoprotein B (Apo-B)
Time frame: Baseline and Week 12
Percent Change from Baseline in Lipoprotein(a) (Lp[a])
Time frame: Baseline and Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.